comp_molregno,act_standard_units,act_standard_type,act_activity_comment,act_bao_endpoint,act_type,ass_assay_id,ass_description,ass_assay_type,ass_assay_category,ass_chembl_id,doc_doi,doc_pubmed_id,doc_chembl_id,doc_title,doc_doc_type,doc_abstract,doc_patent_id,coms_canonical_smiles,comp_full_molformula,mold_chembl_id,act_0
MKKJWHGGPQKIRA-UHFFFAOYSA-N,nM,ID50,,BAO_0000179,ID50,,37335,Antagonist activity at androgen receptor expressed in COS cell by whole cell assay,,,17095226,788,10.1016/j.bmcl.2006.10.071,CHEMBL1138416,"Synthesis and SAR of potent and selective androgen receptor antagonists: 5,6-Dichloro-benzimidazole derivatives.","Ng RA, Guan J, Alford VC, Lanter JC, Allan GF, Sbriscia T, Linton O, Lundeen SG, Sui Z.","The synthesis and in vivo SAR of 5,6-dichloro-benzimidazole derivatives as novel selective androgen receptor antagonists are described. During screening of 2-alkyl benzimidazoles, it was found that a trifluoromethyl group greatly enhances antagonist activity in the prostate. Benzimidazole 1 is a potent AR antagonist in the rat prostate (ID50 = 0.15 mg/day).","InChI=1S/C10H10Cl2N2O/c1-10(2,15)9-13-7-3-5(11)6(12)4-8(7)14-9/h3-4,15H,1-2H3,(H,13,14)",0.81,-0.73,80.0
